Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Medical devices / Surgical and interventional devices / Ambulatory surgery centre and outpatient procedure-device buyers

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Ambulatory surgery centre and outpatient procedure-device buyers

Same surgical, endoscopy and interventional device families bought by freestanding ambulatory surgery centres, outpatient endoscopy suites and office-based labs rather than by hospital ORs. Job is to run high-throughput, standardised, lower-cost procedures with fast room turnover and predictable outcomes.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
70 /100
for B2B sellers
Evidence
not sized
1 source · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Ambulatory surgery centres, outpatient endoscopy centres, office-based labs and physician practice ASCs
Buying centre
ASC executive leadership and materials-management committee, with surgeon-owner or clinical director input and a lean purchasing process
Buying triggers
  • Shift of procedures out of hospital ORs to lower-cost sites
  • ASC chain roll-ups and multi-site procurement consolidation
  • Demand for shorter turnover and higher case throughput
  • Pressure to lower per-case cost versus hospital
  • Single-use and office-based procedure adoption
Pains
  • Small order volumes and limited purchasing leverage
  • Need for fast, reliable supply with minimal on-site inventory
  • Capital budget constraints favouring flexible or per-procedure economics
  • Limited in-house clinical engineering and training resources
Scores (1–5)
Pain intensity3
Purchasing power3
Reachability3
Growth5

How this was sized

Not sized yet

Bottom-up from the hospital-inclusive pool: global surgical, endoscopy and robotic device spend of about USD 200bn in 2026 (31% of USD 620bn 2025 market per [6], grown at the 6.0% CAGR in [6]). Assume ASC and outpatient share of 20-30% of that pool, giving USD 40bn-60bn for 2026. Arithmetic: 200bn x 20% = 40bn; 200bn x 30% = 60bn. Low confidence: the 20-30% share is an assumption; [6] cites procedure-volume growth and the move of care to surgical centres as drivers but gives no ASC device-spend figure.

Alongside it in Surgical and interventional devices

// Sell into Ambulatory surgery centre and outpatient procedure-device buyers

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.